Breast cancer genomic test could spare millions from chemotherapy

The OPTIMA trial presented at ASCO 2026 demonstrated that a genomic test can identify early breast cancer patients who can safely avoid chemotherapy, potentially sparing millions from unnecessary treatment while maintaining positive outcomes.

This does not prove the test works for all breast cancer types, nor does it eliminate the need for chemotherapy in higher-risk cases—it refines patient selection.